Vertex Pharmaceuticals (VRTX) Current Assets (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Current Assets of $11.7 billion for Q1 2026, up 17.2% year-over-year from $10.0 billion in Q1 2025, and up 4.73% quarter-over-quarter from $11.2 billion in Q4 2025.
Vertex Pharmaceuticals (VRTX) Current Assets (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Current Assets history runs 18 years deep, the most recent figure standing at $11.7 billion for Q1 2026.
- In Q1 2026, Current Assets rose 17.2% year-over-year to $11.7 billion; the TTM figure through Mar 2026 stood at $11.7 billion (up 17.2% YoY), while the FY2025 annual figure was $11.2 billion, up 16.72% from the prior year.
- Current Assets for Q1 2026 stood at $11.7 billion, up from $11.2 billion in the prior quarter.
- The five-year high for Current Assets was $14.7 billion in Q3 2023, with the low at $8.9 billion in Q2 2024.
- The 5-year median for Current Assets is $11.5 billion (2022), against an average of $11.7 billion.
- The sharpest annual moves came in 2022 and 2024: Current Assets surged 38.62% in 2022, then tumbled 35.55% in 2024.
- Vertex Pharmaceuticals' Current Assets stood at $13.2 billion in 2022, then climbed by 6.87% to $14.1 billion in 2023, then slumped by 32.15% to $9.6 billion in 2024, then rose by 16.72% to $11.2 billion in 2025, then rose by 4.73% to $11.7 billion in 2026.
- Business Quant data shows VRTX's Current Assets at $11.7 billion in Q1 2026, $11.2 billion in Q4 2025, and $10.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 4.74 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.54 Bn |
| Mar 31, 2026 | 11.73 Bn |
| Dec 31, 2025 | 11.20 Bn |
| Sep 30, 2025 | 10.57 Bn |
| Jun 30, 2025 | 10.43 Bn |
| Mar 31, 2025 | 10.01 Bn |
| Dec 31, 2024 | 9.60 Bn |
| Sep 30, 2024 | 9.80 Bn |
| Jun 30, 2024 | 8.94 Bn |
| Mar 31, 2024 | 13.29 Bn |
| Dec 31, 2023 | 14.14 Bn |
| Sep 30, 2023 | 14.70 Bn |
| Jun 30, 2023 | 13.87 Bn |
| Mar 31, 2023 | 12.97 Bn |
| Dec 31, 2022 | 13.23 Bn |
| Sep 30, 2022 | 12.27 Bn |
| Jun 30, 2022 | 11.50 Bn |
| Mar 31, 2022 | 10.36 Bn |
| Dec 31, 2021 | 9.56 Bn |
| Sep 30, 2021 | 8.85 Bn |